piretanide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diuretics, piretanide derivatives 2201 55837-27-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • piretanide
  • arelix
  • diumax
  • eurelix
potent inhibitor of chloride transport; structure
  • Molecular weight: 362.40
  • Formula: C17H18N2O5S
  • CLOGP: 2.50
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 109.93
  • ALOGS: -3.60
  • ROTB: 5

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.55 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 92 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.17 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1980 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Stevens-Johnson syndrome 69.18 43.66 17 207 23280 46662558
Toxic epidermal necrolysis 49.90 43.66 13 211 22265 46663573
Blood urea increased 48.23 43.66 13 211 25339 46660499

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC C03CA03 CARDIOVASCULAR SYSTEM
DIURETICS
HIGH-CEILING DIURETICS
Sulfonamides, plain
MeSH PA D004232 Diuretics
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D045283 Natriuretic Agents
MeSH PA D049994 Sodium Potassium Chloride Symporter Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Edema indication 267038008

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.58 acidic
pKa2 9.66 acidic
pKa3 3.92 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 12 member 1 Transporter INHIBITOR Kd 8.30 WOMBAT-PK KEGG DRUG
Solute carrier family 12 member 2 Transporter INHIBITOR IC50 5.62 IUPHAR KEGG DRUG

External reference:

IDSource
D01634 KEGG_DRUG
C0591108 UMLSCUI
CHEBI:32015 CHEBI
CHEMBL349803 ChEMBL_ID
41448 PUBCHEM_CID
DB02925 DRUGBANK_ID
4742 IUPHAR_LIGAND_ID
C015451 MESH_SUPPLEMENTAL_RECORD_UI
3741 INN_ID
DQ6KK6GV93 UNII
151370 RXNORM
23252 MMSL
004024 NDDF
318031002 SNOMEDCT_US
419451002 SNOMEDCT_US

Pharmaceutical products:

None